Provided by Tiger Trade Technology Pte. Ltd.

Myriad Genetics

3.86
-0.0200-0.52%
Post-market: 3.73-0.1310-3.39%19:30 EDT
Volume:2.05M
Turnover:8.05M
Market Cap:369.02M
PE:-3.21
High:4.09
Open:3.75
Low:3.75
Close:3.88
52wk High:8.59
52wk Low:2.74
Shares:95.60M
Float Shares:79.40M
Volume Ratio:0.70
T/O Rate:2.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2031
EPS(LYR):-3.9514
ROE:-32.54%
ROA:-8.59%
PB:1.21
PE(LYR):-0.98

Loading ...

Myriad Genetics Down over 45%, on Pace for Record Percent Decrease

Dow Jones
·
Aug 01

Myriad Genetics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 31

Myriad Genetics: Q2 Miss, Guidance Cut Lead to Lower $4 Price Target and Maintained Hold Rating

TIPRANKS
·
Jul 31

Myriad Genetics Lowers FY26 Rev Outlook

Dow Jones
·
Jul 31

Myriad Genetics cuts FY26 revenue view to $770M-$790M from $860M-$880M

TIPRANKS
·
Jul 31

Myriad Genetics reports Q2 EPS (25c), consensus (6c)

TIPRANKS
·
Jul 31

Myriad Genetics Q2 FY26 Operating Loss Narrows to $38.9 Million; Revenue Drops 11% to $190.7 Million

Reuters
·
Jul 31

Myriad Genetics Q2 Adj. EPS $(0.25) Misses $(0.06) Estimate, Sales $190.700M Miss $206.029M Estimate

Benzinga Earnings
·
Jul 31

Myriad Genetics Q2 Revenue USD 190.7 Million Vs. IBES Estimate USD 206 Million

Reuters
·
Jul 31

Myriad Genetics - Suspends Full-Year 2026 Adj Ebitda Guidance

THOMSON REUTERS
·
Jul 31

Myriad Genetics Outlook FY Revenue USD 770-790 Million

THOMSON REUTERS
·
Jul 31

Myriad Genetics Q2 Gross Margin 66.6%

THOMSON REUTERS
·
Jul 31

Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability

THOMSON REUTERS
·
Jul 31

Myriad Genetics Inc Expected to Post a Loss of 6 Cents a Share - Earnings Preview

Reuters
·
Jul 29

Centene Appoints Cressey’s Paul Diaz to Board as Burdick Retires

Reuters
·
Jul 28

Myriad Genetics Schedules Q2 Earnings Conference Call

Reuters
·
Jul 23

Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026

GlobeNewswire
·
Jul 23

Myriad Genetics Launches FirstGene® Multiple Prenatal Screen

GlobeNewswire
·
Jul 21

Myriad Says Meta-analysis Supports Prognostic Performance of Prolaris Biopsy Test in Localized Prostate Cancer

Reuters
·
Jul 02

Sera Prognostics Names Former Myriad Genetics CEO Mark Capone to Board

Reuters
·
Jul 01